Crown Bioscience enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Crown Bioscience announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the d...
Crown Bioscience announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen.
The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in v...
